The company’s lead candidate, laromestrocel, failed to demonstrate a statistically significant improvement in right ventricular ejection fraction at the 12-month mark. In response to the clinical setback, Longeveron is implementing immediate cost-containment measures and intends to hire an investment bank to navigate its next steps. Trading of the company’s shares was briefly halted ahead of the announcement.

Despite the primary failure, management is holding onto a sliver of optimism regarding secondary data. The trial recorded zero deaths among infants treated with the therapy, compared to one fatality in the control group. Longeveron intends to present these findings to the Food and Drug Administration to assess whether a regulatory path remains viable for the condition. Meanwhile, the firm is shifting its focus toward the drug's potential in treating aging-related frailty, hoping to secure new funding and revenue streams from this separate clinical trajectory.